HIND Vyome Holdings, Inc.
USHealthcareAs of 2026-07-02
Why HIND matters now
Vyome Holdings, Inc. (HIND) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.30 with +2.22% on the session and $13.0M in market capitalization; recent performance reads 1-month +7.96% and YTD -36.92%.
The latest financial table shown here is Q1 2026, with revenue of $31.6K, net income of $-962.9K, and EPS of $-0.17. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -25.1%.
The latest indexable market news headline is "Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio" from Business Wire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $15.00. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.90
P/S
9.09
EV/EBITDA
-0.26
DCF Value
$1.85
FCF Yield
-25.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
48.2%
Operating Margin
-401.9%
Net Margin
-985.5%
ROE
-302.1%
ROA
-130.1%
ROIC
-67.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $31.6K | $-962.9K | $-0.17 |
| Q4 2025 | $36.6K | $-1.2M | $-0.21 |
| FY 2025 | $319.7K | $-10.3M | $-4.75 |
| Q3 2025 | $34.6K | $-8.4M | $-29.42 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$15.00
Target (Median)
$15.00
Target Range
$15.00 - $15.00
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.49
Vyome Holdings, Inc. operates as a healthcare firm currently in its clinical development phase, concentrating on the creation of innovative medicinal treatments designed to address both immuno-inflammatory conditions and infrequent disorders. Founded in 2017, the company extends its market reach throughout the United States and into global territories, headquartered in Princeton, New Jersey.